Míriam Arumí

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)

S. Serrano, M. Salido, J. Albanell, 2015, Oncotarget.

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.

A. Prat, P. Villagrasa, A. Llombart-Cussac, 2019, The Lancet. Oncology.

Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field

E. Zamora, M. Bellet, S. Escrivá-de-Romaní, 2018, Breast Care.

HER2-positive breast cancer: Current and new therapeutic strategies.

C. Saura, M. Bellet, S. Escrivá-de-Romaní, 2018, Breast.

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

J. Gavilá, M. Atienza, E. Aguirre, 2023, Clinical and Translational Oncology.